Form : Tablets
/ Pack : 10 X 10’s
/ Type : Alu Alu
Description : Compared for the first time; the efficacy and safety of concomitant administration of bilastine with montelukast vs respective monotherapies in a large population of patients with SARC and asthma, contrary to our original hypothesis, concomitant administration of bilastine with montelukast was effective as either agent alone in the treatment of SARC symptoms.
Reports suggest that an improvement in SARC can also improve asthma control - Allergy. 2020 Mar; 75(3): 675–677.
Description : On a clinical level, acebrophylline is therapeutically effective in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis and recurrence of chronic bronchitis; it reduces the frequency of episodes of bronchial obstruction and reduces the need for beta 2- Agonists and improves indexes of ventilatory function- Monaldi Arch Chest Dis. 2007 Jun;67(2):106-15.
The acetylated variant of the amino acid L- Cysteine, is an excellent source of sulfhydryl (SH) groups, and is converted in the body into metabolites capable of stimulating glutathione (GSH) synthesis, promoting detoxification, and acting directly as free radical scavengers - Altern Med Rev.1998 Apr;3(2):114-27.
Category: Respiratory
Form : Respirator Solution
/ Pack : 10 x 5 x 2.5ml
/ Type : Combipack Respules
Description : Levosalbutamol being a functional short-acting Beta 2 adrenergic receptor agonist, relaxes the smooth muscles from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, irrespective of the spasmogen involved, thereby protecting against all broncho-constrictor challenges. Ipratropium Bromide (IB) specifically has emerged as the overwhelming choice of pulmonologists and emergency physicians because of its limited systemic absorption from the lungs when given as an inhaled preparation. However, although the varying trials, predominantly in the emergency department setting, have typically shown a trend toward improved outcomes - Pediatr Emerg Care. 2009 Oct; 25(10):687-92.
Form : Inhaler
/ Pack : 1 X 1's
/ Type : 120 Metered Doses
Description : Budesonide inhaler is used to prevent difficulty breathing, chest tightness, wheezing, and coughing caused by asthma. Budesonide powder for oral inhalation is used in adults and children 6 years of age and older. Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity.. Vodaryl -200 inhaler is designed to provide 120 inhalations. After 120 inhalations the device may not contain the correct amount of medication, so keep record of the number of inhalations used.
Form : Respirator Suspension
/ Pack : 5 x 5 x 2ml
/ Type : Combipack Respules
Description : Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity. Budesonide is used to control and prevent symptoms such as wheezing, shortness of breath caused by asthma. Used as maintenance treatment of asthma and as a prophylactic therapy in children 12 months to 8 years of age
Composition : Formoterol Fumarate 6mcg + Budesonide 200mcg Per Actuation
Form : Inhaler
/ Pack : 1 x 1's
/ Type : 120 Metered Doses
Description : Formoterol is a very potent, long-acting, beta-2 adrenoceptor-agonist with a high intrinsic activity and a rapid onset of action Where as Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity. The combination medicine has different modes of action and show additive effects in terms of reduction of asthma exacerbations thus used to control and prevent the symptoms of asthma in adults and children above 6 years old. Formoterol & Budesonide is also used to help control the symptoms of chronic obstructive pulmonary disease (COPD), including chronic bronchitis
Form : Tablets
/ Pack : 10 x 10"s
/ Type : ALU ALU
Description : Acebrophylline is an airway mucus regulator with antiinflammatory action. The drug's approach involves several points of attack in obstructive airway disease. The molecule contains ambroxol, which facilitates various steps in the biosynthesis of pulmonary surfactant, theophylline-7 acetic acid whose carrier function raises blood levels of ambroxol, thus rapidly and intensely stimulating surfactant production. The resulting reduction in the viscosity and adhesivity of the mucus greatly improves ciliary clearance. By deviating phosphatidylcholine towards surfactant synthesis, making it no longer available for the synthesis of inflammatory mediators such as the leukotrienes, acebrophylline also exerts an inflammatory effect. This is confirmed in vivo by the reduction in aspecific bronchial hyper-responsiveness in patients with stable bronchial asthma. On a clinical level, acebrophylline is therapeutically effective in patients with acute or chronic bronchitis, chronic obstructive or asthma-like bronchitis and recurrence of chronic bronchitis; it reduces the frequency of episodes of bronchial obstruction and reduces the need for beta2-agonists, and improves indexes of ventilatory function- Monaldi Arch Chest Dis. 2007 Jun;67(2):106-15.
Description : The literature search establishes that addition of fexofenadine to montelukast has added benefit. The combination therapy of montelukast with fexofenadine provide enhancing and complimentary effects thereby reducing the symptoms effectively- – Indian journal of Pharmacology; 2016; Vol : 48; Issue : 6; Page : 649-653
Fexofenadine 120 mg + Montelukast 10mg fixed dose combination (FDC) was bioequivalent to individual tablets of fexofenadine & montelukast of the same strengths administered concurrently. No serious AEs were observed with fexofenadine 120mg + montelukast 10mg FDC. The tolerability of the FDC was comparable to that of the co-administered individual components. With the availability of an FDC tablet, patients suffering from allergic rhinitis will have a more convenient option to improve treatment compliance and adherence - Indian Journal of Pharmaceutical Sciences, pp 651- 656, Sept.- Oct. 2016
Description : Compared with montelukast monotherapy, montelukast plus levocetirizine demonstrated a significant reduction in MDNSS (least squares mean ± standard error of combination vs montelukast, –0.98±0.06 vs –0.81±0.06, respectively; P = .045). Regarding all other allergic rhinitis efficacy end points, the combination therapy group experienced greater improvements compared with the montelukast monotherapy group. Similar results were reported with respect to overall assessment scores, as well as FEV1, FVC, FEV1/FVC, and ACT score changes from baseline in the 2 treatment arms. Montelukast plus levocetirizine was well tolerated, with a safety profile similar to that reported for montelukast monotherapy. The investigators concluded that the fixed-dose combination of montelukast plus levocetirizine was effective and safe for the treatment of perennial allergic rhinitis and asthma - Pulmonology Advisor‘s- CHEST 2018
Description : The literature search establishes that addition of fexofenadine to montelukast has added benefit. The combination therapy of montelukast with fexofenadine provide enhancing and complimentary effects thereby reducing the symptoms effectively- Indian journal of Pharmacology; 2016; Vol : 48; Issue : 6; Page : 649-653
A comparable clinical improvement of symptoms score and spirometric parameters with both the drugs (Acebrophylline vs Sustained Release Theophylline) has been observed (p-value>0.05). Amount of sputum, frequency of use of reliever medication and dyspnoea showed improvement with both the drugs but cardiovascular side effects are less with Acebrophylline - J Clin Diagn Res. 2014 Sep;8(9)
